Phase 1/2 Study of BH-30643 in NSCLC with EGFR/HER2 Mutations Initiated by BlossomHill Therapeutics
BlossomHill Therapeutics has initiated Phase 1/2 study of BH-30643 targeting NSCLC patients with EGFR and/or HER2 mutations.
Phase I
Oncology / NSCLC
Status
Initiated
Sponsor
BlossomHill Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the Phase 1/2 study of BH-30643 by BlossomHill Therapeutics is significant as it targets a specific patient population with EGFR and/or HER2 mutations in NSCLC. The outcomes of this trial could reshape treatment paradigms and influence competitive positioning in the oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the determination of the RP2D and MTD, as well as preliminary efficacy results from the Phase 2 portion of the trial.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.